Theriva Biologics Inc.

04/10/2025 | Press release | Archived content

Theriva Biologics anuncia la presentación de los datos del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Theriva Biologics Inc. published this content on April 10, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 17, 2025 at 02:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]